Koyfin Home > Directory > Health Care > Revance Therapeutics > EV / Sales (ntm)

Revance Therapeutics EV / Sales (ntm) Chart (RVNC)

Revance Therapeutics annual/quarterly EV / Sales (ntm) from 2018 to 2020.
  • Revance Therapeutics EV / Sales (ntm) for the quarter ending September 09, 2020 was 46.10 a -5.49% decrease of -2.53 year over year
  • Revance Therapeutics EV / Sales (ntm) for the last 12 months ending September 09, 2020 was 46.10 a -5.49% decrease of -2.53 year over year
  • Revance Therapeutics Annual EV / Sales (ntm) for 2020 was 46.10 a -0.58% decrease of -0.27 from 2019
  • Revance Therapeutics Annual EV / Sales (ntm) for 2020 was 46.37 a -7.91% decrease of -3.67 from 2019
  • Revance Therapeutics Annual EV / Sales (ntm) for 2020 was 50.04 a 2.81% increase of 1.41 from 2019
Other Valuation Metrics:
  • Revance Therapeutics Market Cap for the quarter ending March 03, 2018 was $1,131m a 29.36% increase of 332m year over year
  • Revance Therapeutics Price / Book for the quarter ending March 03, 2018 was 4.18 a -6.42% decrease of -0.27 year over year
  • Revance Therapeutics Enterprise Value for the quarter ending March 03, 2018 was $850m a 27.67% increase of 235m year over year
View Chart On Koyfin

Quarterly RVNC EV / Sales (ntm) Data

09/202046.10
09/202046.37
09/202050.04
09/202048.63
09/202041.76
09/202039.73
09/202039.11
09/202040.84
09/202038.16
09/202038.01

Annual RVNC EV / Sales (ntm) Data

202046.10
202046.37
202050.04
202048.63
202041.76
202039.73
202039.11
202040.84
202038.16
202038.01